Adjustments of iodinated contrast media using lean body weight for abdominopelvic computed tomography: A systematic review and meta-analysis

PURPOSE

This systematic review aimed to compare the effect of contrast media (CM) dose adjustment based on lean body weight (LBW) method versus other calculation protocols for abdominopelvic CT examinations.

METHOD

Studies published from 2002 onwards were systematically searched in June 2024 across Medline, Embase, CINAHL, Cochrane CENTRAL, Web of Science, Google Scholar and four other grey literature sources, with no language limit. Randomised controlled trials (RCT) and quasi-RCT of abdominopelvic or abdominal CT examinations in adults with contrast media injection for oncological and acute diseases were included. The comparators were other contrast dose calculation methods such as total body weight (TBW), fixed volume (FV), body surface area (BSA), and blood volume. The main outcomes considered were liver and aortic enhancement. Titles, abstracts and full texts were independently screened by two reviewers.

RESULTS

Eight studies were included from a total of 2029 articles identified. Liver parenchyma and aorta contrast enhancement did not significantly differ between LBW and TBW protocols (p = 0.07, p = 0.06, respectively). However, the meta-analysis revealed significantly lower contrast volume injected with LBW protocol when compared to TBW protocol (p = 0.003). No statistical differences were found for contrast enhancement and contrast volume between LBW and the other strategies.

CONCLUSION

Calculation of the CM dosage based on LBW allows a reduction in the injected volume for abdominopelvic CT examination, ensuring the same image quality in terms of contrast enhancement.

[Investigation of the Correlation between Patient Characteristics and Contrast Enhancement during Hepatic Dynamic CT Scan: Comparison by the Sex]

The purpose of this study was to investigate the correlation between patient characteristics and contrast enhancement during the hepatic arterial phase (HAP) and portal venous phase (PVP) CT scanning. All were examined using a hepatic dynamic CT protocol; the scanning parameters were tube voltage 120 kVp, tube current 50 to 600 mA (noise index 8.0 HU), 0.5-s rotation, 5-mm detector row width, 0.813 or 0.825 beam pitch, and the contrast material 600 mg/kg iodine. We calculated contrast enhancement (per gram of iodine: ΔHU/gI) of the abdominal aorta during the HAP and that of the hepatic parenchyma during the PVP. There was a significant difference in the contrast enhancement of the abdominal aorta during the HAP (8.6±2.7 ΔHU/gI) and (9.5±1.7 ΔHU/gI) and that of the hepatic parenchyma during the PVP (1.4±0.5 ΔHU/gI) and (2.9±0.5 ΔHU/gI) between male and female patients (p<0.05). A significant positive correlation was seen between the ΔHU/gI of aortic enhancement and age in male and female patients (r=-0.382 and 0.213) (p<0.05). A significant inverse correlation was observed between the ΔHU/gI of aortic enhancement and the height (HT; r=-0.466 and -0.251), total body weight (TBW; r=-0.609 and -0.535), body mass index (BMI; r=-0.505 and -0.465), lean body weight (LBW; r=-0.642 and -0.576), and body surface area (BSA; r=-0.644 and -0.557) (p<0.05 for all) in male and female patients. A significant positive correlation was seen between the ΔHU/gI of hepatic parenchymal enhancement and the patient age in male and female patients (r=0.258 and 0.150) (p<0.05). A significant inverse correlation was observed between the ΔHU/gI of hepatic parenchymal enhancement and the HT (r=-0.487 and -0.321), TBW (r=-0.580 and -0.525), BMI (r=-0.473 and -0.413), LBW (r=-0.615 and -0.576) (p<0.05 for all), and BSA (r=-0.617 and -0.558) in male and female patients. The BSA was significantly correlated with the ΔHU/gI of aortic and hepatic parenchymal enhancement of the hepatic dynamic CT in male patients. However, LBW was significantly correlated with the ΔHU/gI of aortic and hepatic parenchymal enhancement of the hepatic dynamic CT in female patients. Since the patient factors that affect the contrast enhancement of the abdominal aorta and hepatic parenchyma may differ from facility to facility, we should therefore consider reassessing at each facility.

The Feasibility of Using a Deep Learning-Based Model to Determine Cardiac Computed Tomographic Contrast Dose

PURPOSE

This study aimed to predict contrast effects in cardiac computed tomography (CT) from CT localizer radiographs using a deep learning (DL) model and to compare the prediction performance of the DL model with that of conventional models based on patients' physical size.

METHODS

This retrospective study included 473 (256 men and 217 women) cardiac CT scans between May 2014 and August 2017. We developed and evaluated DL models that predict milligrams of iodine per enhancement of the aorta from CT localizer radiographs. To assess the model performance, we calculated and compared Pearson correlation coefficient ( r ) between the actual iodine dose that was necessary to obtain a contrast effect of 1 HU (iodine dose per contrast effect [IDCE]) and IDCE predicted by DL, body weight, lean body weight, and body surface area of patients.

RESULTS

The model was tested on 52 cases for the male group (mean [SD] age, 63.7 ± 11.4) and 44 cases for the female group (mean [SD] age, 69.8 ± 11.6). Correlation coefficients between the actual and predicted IDCE were 0.607 for the male group and 0.412 for the female group, which were higher than the correlation coefficients between the actual IDCE and body weight (0.539 for male, 0.290 for female), lean body weight (0.563 for male, 0.352 for female), and body surface area (0.587 for male, 0.349 for female).

CONCLUSIONS

The performance for predicting contrast effects by analyzing CT localizer radiographs with the DL model was at least comparable with conventional methods using the patient's body size, notwithstanding that no additional measurements other than CT localizer radiographs were required.

Influence of splenomegaly on aortic and liver parenchymal CT numbers during contrast-enhance CT in patients with cirrhosis

INTRODUCTION

To compare CT (computed tomography) values for enhancement of the abdominal aorta and liver parenchyma during dynamic contrast enhancement (CE) CT in cirrhotic patients with and without splenomegaly (SM).

METHODS

We considered 258 patients (83 males and 46 females for the splenomegaly group, and 83 males and 46 females for the control group) for this retrospective study. We measured CT values in the abdominal aorta and hepatic parenchyma during the hepatic arterial (HAP) and portal venous (PVP) phases. The aortic CE at HAP and the hepatic parenchymal CE at PVP were compared between the two groups. For success rate of scans, we also calculated the optimal CE rates (>280 HU in the abdominal aorta and >50 HU in the hepatic parenchyma) for each group.

RESULTS

In the SM group, the CE for abdominal aorta was decreased during the aortic phase for a dynamic CE-CT (p < 0.05). When evaluating the success rates, they were found to be 65.1 % and 58.9 % in the SM group and 81.4 % and 72.3 % in the non-SM group (p < 0.05).

CONCLUSION

The success rate of scans and CE for the abdominal aorta during the aortic phase exhibited a significant decrease during dynamic CE-CT scans on patients with SM. Patients with SM may have reduced diagnostic ability with typical contrast injection protocols.

IMPLICATIONS FOR PRACTICE

It may be necessary to change the injection rates and contrast medium volume during CE-CT depending on the presence or absence of SM.

Estimating the differences between inter-operator contrast enhancement in cerebral CT angiography

BACKGROUND

Computed tomography (CT) angiography (CTA) is a non-invasive imaging method used to detect arteries and examine various brain diseases. When CTA is performed for follow-up or postoperative evaluation, reproducibility of vessel delineation is required. A reproducible and stable contrast enhancement can be achieved by manipulating the factors affecting it. Previous studies have investigated several factors that alter the contrast enhancement of arteries. However, no reports establishing the effect of different operators on contrast enhancement exist.

PURPOSE

To assess the differences between inter-operator arterial contrast enhancement in cerebral CTA using Bayesian statistical modeling.

METHODS

Image data were obtained using a multistage sampling method from the cerebral CTA scans of patients who underwent the process between January 2015 and December 2018. Several Bayesian statistical models were developed, and the objective variable was the mean CT number of the bilateral internal carotid arteries after contrast enhancement. The explanatory variables were sex, age, fractional dose (FD), and the operator's information. The posterior distributions of the parameters were computed via Bayesian inference using the Markov chain Monte Carlo (MCMC) method, with the Hamiltonian Monte Carlo method employed as the algorithm. The posterior predictive distributions were computed using the posterior distributions of the parameters. Finally, the differences between inter-operator arterial contrast enhancement on the CT number in cerebral CTA were estimated.

RESULTS

The posterior distributions showed that all parameters representing the difference between operators included zero at the 95% credible intervals (CIs). The maximum mean difference between inter-operator CT number in the posterior predictive distribution was only 12.59 Hounsfield units (HUs).

CONCLUSIONS

The Bayesian statistical modeling results suggest that contrast enhancement of cerebral CTA examination between operator-to-operator differences in postcontrast CT number was small compared to those within-operator differences resulting from factors not considered in the model.

The hemodynamics of adrenal veins with four-dimensional computed tomography using quantitative time-density curve: a study based on aldosteronism patients

Present study quantitatively analyzed adrenal venous flow using four-dimensional computed tomography (4D CT). We reviewed 4D CT images of 55 patients [mean age, 52 years ± 11 (standard deviation); 23 females] who underwent adrenal venous sampling between August 2017 and February 2021. Time-density curves were referred for the adrenal venous enhancement. The clinical factors affecting hemodynamics were assessed using uni- and multivariate linear regression analyses. The right and left adrenal veins (RAV and LAV, respectively) were visualized in all cases. Mean peak enhancement values in RAV and LAV were 247 ± 67 and 292 ± 70 Hounsfield units (P < 0.01), and were reached at 44.43 ± 6.86 and 45.39 ± 7.53 s (P < 0.01), respectively. The body mass index (BMI), plasma renin activity and potassium were significant factors influencing the peak enhancement of RAV blood flow [standardized regression coefficients, - 0.327 (P = 0.017), - 0.346 (P = 0.013), 0.426 (P = 0.016), respectively]. A linear relationship between sex and the time-to-peak was observed for RAV [standardized regression coefficient, 0.348 (P = 0.046)]. RAV had a lower contrast effect than LAV and reached its peak faster. BMI, plasma renin activity, and potassium were associated with flow density in RAV. Sex independently influenced the time-to-peak.

Can Machine Learning Identify the Intravenous Contrast Dose and Injection Rate Needed for Optimal Enhancement on Dynamic Liver Computed Tomography?

OBJECTIVES

This study aimed to investigate whether machine learning (ML) is useful for predicting the contrast material (CM) dose required to obtain a clinically optimal contrast enhancement in hepatic dynamic computed tomography (CT).

METHODS

We trained and evaluated ensemble ML regressors to predict the CM doses needed for optimal enhancement in hepatic dynamic CT using 236 patients for a training data set and 94 patients for a test data set. After the ML training, we randomly divided using the ML-based (n = 100) and the body weight (BW)-based protocols (n = 100) by the prospective trial. The BW protocol was performed using routine protocol (600 mg/kg of iodine) by the prospective trial. The CT numbers of the abdominal aorta and hepatic parenchyma, CM dose, and injection rate were compared between each protocol using the paired t test. Equivalence tests were performed with equivalent margins of 100 and 20 Hounsfield units for the aorta and liver, respectively.

RESULTS

The CM dose and injection rate for the ML and BW protocols were 112.3 mL and 3.7 mL/s, and 118.0 mL and 3.9 mL/s (P < 0.05). There were no significant differences in the CT numbers of the abdominal aorta and hepatic parenchyma between the 2 protocols (P = 0.20 and 0.45). The 95% confidence interval for the difference in the CT number of the abdominal aorta and hepatic parenchyma between 2 protocols was within the range of predetermined equivalence margins.

CONCLUSIONS

Machine learning is useful for predicting the CM dose and injection rate required to obtain the optimal clinical contrast enhancement for hepatic dynamic CT without reducing the CT number of the abdominal aorta and hepatic parenchyma.

Hepatic enhancement at computed tomography: is there a dependence on body weight past institutional contrast dosing limits?

BACKGROUND

Although described in product monographs, the maximum contrast media (CM) dose at computed tomography (CT) varies among institutions.

PURPOSE

To investigate whether an upper limit of 40 g of iodine in women and 50 g in men is sufficient or if there is a body weight (BW) dependence of mean hepatic enhancement (MHE) beyond those thresholds.

MATERIAL AND METHODS

At our institution, CM injection duration is fixed to 30 s and dosed 600 mg iodine/kg up to 40 g in women and 50 g in men. Pre- and post-contrast hepatic attenuation values (HU) were retrospectively obtained in 200 women and 200 men with glomerular filtration rate >45 mL/min undergoing 18-flurodeoxyglucose PET-CT (18F-FDG PET-CT) of which half weighed below and half above those dose thresholds using iodixanol 320 mg iodine/mL or iomeprol 400 mg iodine/mL. The correlation between BW and MHE was assessed by simple linear regression.

RESULTS

Weight range was 41-120 kg in women and 47-137 kg in men. There was no significant relationship between MHE and BW in women receiving <40 g (r = -0.05, P = 0.63) or in men receiving <50 g (r = 0.18, P = 0.07). Above those thresholds there was an inverse relationship (r = -0.64, P<0.001 in women and r = -0.30, P<0.002 in men). There was no apparent upper limit where the dependence of hepatic MHE on BW decreased. Hepatosteatosis limited MHE.

CONCLUSION

Adjusting CM to BW diminishes the dependence of MHE on BW. There was no apparent upper limit for the relationship between BW and MHE in heavier patients at CM-enhanced CT.

Evaluation of Iodinated Contrast Media Use in Abdominal CT Scans in Cancer Assessments: A Cross-Sectional Study in Lomé (Togo)

Background

There is great variability between centers regarding contrast injection protocols. They should only be injected if they can provide useful information for diagnosis with the necessary and sufficient quantity of iodine. We wanted to know through this study if the use of iodinated contrast media is optimised in abdominal CT scans performed for cancer assessment in Lomé.

Materials and Methods

It was a cross-sectional, descriptive, and analytical study with a prospective collection over a period of 6 months in three CT units in Lomé. It involved abdominal CT scans performed for oncological evaluation. Data were reported as the mean ± standard deviation. The Pearson correlation coefficient, ANOVA, chi-square, and the Fisher test were used.

Results

A total of 218 examinations were recorded. The female sex represented 56.88% of the patients. The mean age was 50.92 ± 15.78 years. The mean weight was 70.46 ± 15.23 kg. The mean BMI was 24.91 ± 5.32 kg/m². The examinations were performed with a voltage of 120 kV in 195 cases (89.45%). The mean dose of injected iodine was 0.42 ± 0.09 gI/kg with a dose of 0.40 gI/kg at 80 kV and 0.45 gI/kg at 130 kV. The mean injection rate was 2.90 ± 0.34 mL/s. The mean injected volume was 83.19 ± 7.29 mL. The mean duration of the injection was 30.60 ± 7.39 s. The mean iodine delivery rate was 0.98 ± 0.17 gI/s. There was no saline injection in 152 cases (69.72%). Liver contrast enhancement was satisfactory in 94.5% of cases. There was a strong negative linear correlation between the dose of injected iodine and weight.

Conclusions

Optimization guidelines for the use of iodinated contrast media are not always applied. Therefore, monitoring and benchmarking programmes for iodinated contrast injection protocols that involve all radiology personnel should be implemented.

Low-contrast-dose liver CT using low monoenergetic images with deep learning-based denoising for assessing hepatocellular carcinoma: a randomized controlled noninferiority trial

OBJECTIVE

Low monoenergetic images obtained using noise-reduction techniques may reduce CT contrast media requirements. We aimed to investigate the effectiveness of low-contrast-dose CT using dual-energy CT and deep learning-based denoising (DLD) techniques in patients at high risk of hepatocellular carcinoma (HCC).

METHODS

We performed a prospective, randomized controlled noninferiority trial at a tertiary hospital between June 2019 and August 2020 (NCT04027556). Patients at high risk of HCC were randomly assigned (1:1) to the standard-contrast-dose group or low-contrast-dose group, which targeted a 40% reduction in contrast medium dose based on lean body weight. HCC conspicuity on arterial phase images was the primary endpoint with a noninferiority margin of 0.2. Images were independently assessed by three radiologists; model-based iterative reconstruction (MBIR) images of the standard-contrast-dose group and low monoenergetic (50-keV) DLD images of the low-contrast-dose group were compared using a generalized estimating equation.

RESULTS

Ninety participants (age 59 ± 10 years; 68 men) were analyzed. Compared with the standard-contrast-dose group (n = 47), 40% less contrast media was used in the low-contrast-dose group (n = 43) (107.0 ± 17.1 mL vs. 64.5 ± 11.3 mL, p < 0.001). In the arterial phase, HCC conspicuity on 50-keV DLD images in the low-contrast-dose group was noninferior to that of MBIR images in the standard-contrast-dose group (2.92 vs. 2.56; difference, 0.36; 95% confidence interval, -0.13 to ∞; p = 0.013).

CONCLUSIONS

The contrast dose in liver CT can be reduced by 40% without impairing HCC conspicuity when using 50-keV and DLD techniques.

KEY POINTS

• In the arterial phase, hepatocellular carcinoma conspicuity on 50-keV deep learning-based denoising images in the low-contrast-dose group was noninferior to that of model-based iterative reconstruction images in the standard-contrast-dose group. • HCC detection was comparable between 50-keV deep learning-based denoising images in the low-contrast-dose group and model-based iterative reconstruction images in the standard-contrast-dose group.

A patient- and acquisition-tailored injection approach for improving consistency of CT enhancement towards a target CT value in coronary CT angiography

BACKGROUND

Unoptimized coronary CT angiography (CTA) exams typically result in a highly variable arterial enhancement (HU_a ) across patients. This study aimed at harmonizing arterial enhancement by implementing a patient-, contrast- and kV-tailored injection protocol.

METHODS

First, the optimal body size metric to predict HU_a was identified by retrospectively analysing images of 76 patients, acquired with 70 ml contrast media (G1). Second, using phantom experiments, correction factors for the effect of kV and contrast concentration on HU_a were determined. Third, a model was developed, prescribing the optimal contrast dose to be injected to obtain a diagnostically appropriate arterial target enhancement HU_target . The model was then validated on 278 prospectively collected patients, in two groups with two different HU_target : 525 HU (207 patients, G2A) and 425 HU (71 patients, G2B). The HU_a histograms were compared among groups and to the target enhancement through their mean and standard deviation (SD) at 100 kVp reference level. Also, signal-to-noise ratio was obtained and compared among the groups.

RESULTS

Fat free mass (FFM) showed the highest correlation with HU_a (r = 0.69). KVp correction factors ranged from 0.65 at 70 kVp to 1.22 at 140 kVp. The obtained model reduced the group heterogeneity (SD) from 101HU for reference G1 to 75HU (p < 0.001) for G2A and 68HU (p < 0.001) for G2B. The mean HU_a of 506HU in G2A was slightly below HU_target  = 525HU (p = 0.01) whereas in G2B, the mean HU_a of 414HU was not significantly different from HU_target  = 425HU (p = 0.54). The total iodine dose was lowered from 19.5 g-I to 17.6 g-I and 14.2 g-I from G1 to G2A and G2B, on average.

CONCLUSION

A contrast injection model, based on patient's fat free mass and accounting for the contrast agent concentration and the planned CT-scan tube voltage, harmonized arterial enhancement among patients towards a predefined target enhancement in coronary CTA scanning, without affecting the bolus timing.

Prediction of Aortic Contrast Enhancement on Dynamic Hepatic Computed Tomography-Performance Comparison of Machine Learning Methods and Simulation Software

OBJECTIVES

The aim of this study was to compare prediction ability between ensemble machine learning (ML) methods and simulation software for aortic contrast enhancement on dynamic hepatic computed tomography.

METHODS

We divided 339 human hepatic dynamic computed tomography scans into 2 groups. One group consisted of 279 scans used to create cross-validation data sets, the other group of 60 scans were used as test data sets. To evaluate the effect of the patient characteristics on enhancement, we calculated changes in the contrast medium dose per enhancement of the abdominal aorta in the hepatic arterial phase. The parameters for ML were the patient sex, age, height, body weight, body mass index, and cardiac output. We trained 9 ML regressors by applying 5-fold cross-validation, integrated the predictions of all ML regressors for ensemble learning and the simulations, and used the training and test data to compare their Pearson correlation coefficients.

RESULTS

Comparison of different ML methods showed that the Pearson correlation coefficient for the real and predicted contrast medium dose per enhancement of the abdominal aorta was highest with ensemble ML (r = 0.786). It was higher than that obtained with the simulation software (r = 0.350). With ensemble ML, the Bland-Altman limit of agreement [mean difference, 5.26 Hounsfield units (HU); 95% limit of agreement, -112.88 to 123.40 HU] was narrower than that obtained with the simulation software (mean difference, 11.70 HU; 95% limit of agreement, -164.71 to 188.11 HU).

CONCLUSION

The performance for predicting contrast enhancement of the abdominal aorta in the hepatic arterial phase was higher with ensemble ML than with the simulation software.

Influence of Contrast Material Temperature on Patient Comfort and Image Quality in Computed Tomography of the Abdomen: A Randomized Controlled Trial

BACKGROUND

International guideline recommendations on safe use of contrast media (CM) are conflicting regarding the necessity to prewarm iodinated CM.

PURPOSE

Aim of the study was to evaluate the effects of room temperature CM compared with prewarmed CM on image quality, safety, and patient comfort in abdominal computed tomography (CT).

METHODS

CATCHY (Contrast Media Temperature and Patient Comfort in Computed Tomography of the Abdomen) is a double-blinded, randomized noninferiority trial. Between February and August 2020, 218 participants referred for portal venous abdominal CT were prospectively and randomly assigned to 1 of 2 groups. All patients received iopromide at 300 mg I/mL: group 1 at room temperature (~23°C [~73°F]) and group 2 prewarmed to body temperature (37°C [99°F]). A state-of-the-art individualized CM injection protocol was used, based on body weight and adapted to tube voltage. Primary outcome was absolute difference in mean liver attenuation between groups, calculated with a 2-sided 95% confidence interval. The noninferiority margin was set at -10 HU. Secondary outcomes were objective (signal-to-noise ratio and contrast-to-noise ratio) and subjective image quality; CM extravasations and other adverse events; and participant comfort (5-point scale questionnaire) and pain (numeric rating scale). This trial is registered with ClinicalTrials.gov (NCT04249479).

RESULTS

The absolute difference in mean attenuation between groups was + 4.23 HU (95% confidence interval, +0.35 to +8.11; mean attenuation, 122.2 ± 13.1 HU in group 1, 118.0 ± 15.9 HU in group 2; P = 0.03). Signal-to-noise ratio, contrast-to-noise ratio, and subjective image quality were not significantly different between groups (P = 0.53, 0.23, and 0.99 respectively). Contrast extravasation occurred in 1 patient (group 2), and no other adverse events occurred. Comfort scores were significantly higher in group 1 than in group 2 (P = 0.03); pain did not significantly differ (perceived P > 0.99; intensity P = 0.20).

CONCLUSIONS

Not prewarming iodinated CM was found noninferior in abdominal CT imaging. Prewarming conferred no beneficial effect on image quality, safety, and comfort, and might therefore no longer be considered a prerequisite in state-of-the art injection protocols for parenchymal imaging.

Lean body weight-adjusted intravenous iodinated contrast dose for abdominal CT in dogs reduces interpatient enhancement variability while providing diagnostic quality organ enhancement

Contrast-enhanced computed tomography (CECT) is increasingly used to screen for abdominal pathology in dogs, and the contrast dose used is commonly calculated as a linear function of total body weight (TBW). Body fat is not metabolically active and contributes little to dispersing or diluting contrast medium (CM) in the blood. This prospective, analytic, cross-section design pilot study aimed to establish the feasibility of intravenous CM dosed according to lean body weight (LBW) for abdominal CECT in dogs compared to TBW. We hypothesized that when dosing intravenous CM according to LBW, studies will remain at diagnostic quality, there will be a reduced interindividual contrast enhancement (CE) variability, and there will be less change to heart rate and blood pressure in dogs compared to when administering CM calculated on TBW. Twelve dogs had two CECT studies with contrast doses according to TBW and LBW at least 8 weeks apart. Interindividual organ and vessel CE variability, diagnostic quality of the studies, and changes in physiological status were compared between protocols. The LBW-based protocol provided less variability in the CE of most organs and vessels (except the aorta). When dosed according to LBW, liver enhancement was positively associated with grams of iodine per kg TBW during the portal venous phase (P = 0.046). There was no significant difference in physiological parameters after CM administration between dosing protocols. Our conclusion is that a CM dose based on LBW for abdominal CECT lowers interindividual CE variability and is effective at maintaining studies of diagnostic quality.

Individualized Scan Protocols in Abdominal Computed Tomography: Radiation Versus Contrast Media Dose Optimization

BACKGROUND

In contrast-enhanced abdominal computed tomography (CT), radiation and contrast media (CM) injection protocols are closely linked to each other, and therefore a combination is the basis for achieving optimal image quality. However, most studies focus on optimizing one or the other parameter separately.

PURPOSE

Reducing radiation dose may be most important for a young patient or a population in need of repetitive scanning, whereas CM reduction might be key in a population with insufficient renal function. The recently introduced technical solution, in the form of an automated tube voltage selection (ATVS) slider, might be helpful in this respect. The aim of the current study was to systematically evaluate feasibility of optimizing either radiation or CM dose in abdominal imaging compared with a combined approach.

METHODS

Six Göttingen minipigs (mean weight, 38.9 ± 4.8 kg) were scanned on a third-generation dual-source CT. Automated tube voltage selection and automated tube current modulation techniques were used, with quality reference values of 120 kVref and 210 mAsref. Automated tube voltage selection was set at 90 kV semimode. Three different abdominal scan and CM protocols were compared intraindividually: (1) the standard "combined" protocol, with the ATVS slider position set at 7 and a body weight-adapted CM injection protocol of 350 mg I/kg body weight, iodine delivery rate (IDR) of 1.1 g I/s; (2) the CM dose-saving protocol, with the ATVS slider set at 3 and CM dose lowered to 294 mg I/kg, resulting in a lower IDR of 0.9 g I/s; (3) the radiation dose-saving protocol, with the ATVS slider position set at 11 and a CM dose of 441 mg I/kg and an IDR 1.3 g I/s, respectively. Scans were performed with each protocol in arterial, portal venous, and delayed phase. Objective image quality was evaluated by measuring the attenuation in Hounsfield units, signal-to-noise ratio, and contrast-to-noise ratio of the liver parenchyma. The overall image quality, contrast quality, noise, and lesion detection capability were rated on a 5-point Likert scale (1 = excellent, 5 = very poor). Protocols were compared for objective image quality parameters using 1-way analysis of variance and for subjective image quality parameters using Friedman test.

RESULTS

The mean radiation doses were 5.2 ± 1.7 mGy for the standard protocol, 7.1 ± 2.0 mGy for the CM dose-saving protocol, and 3.8 ± 0.4 mGy for the radiation dose-saving protocol. The mean total iodine load in these groups was 13.7 ± 1.7, 11.4 ± 1.4, and 17.2 ± 2.1 g, respectively. No significant differences in subjective overall image or contrast quality were found. Signal-to-noise ratio and contrast-to-noise ratio were not significantly different between protocols in any scan phase. Significantly more noise was seen when using the radiation dose-saving protocol (P < 0.01). In portal venous and delayed phases, the mean attenuation of the liver parenchyma significantly differed between protocols (P < 0.001). Lesion detection was significantly better in portal venous phase using the CM dose-saving protocol compared with the radiation dose-saving protocol (P = 0.037).

CONCLUSIONS

In this experimental setup, optimizing either radiation (-26%) or CM dose (-16%) is feasible in abdominal CT imaging. Individualizing either radiation or CM dose leads to comparable objective and subjective image quality. Personalized abdominal CT examination protocols can thus be tailored to individual risk assessment and might offer additional degrees of freedom.

Enhancement rate of venous phase to portal venous phase computed tomography and its correlation with ultrasound elastography determination of liver fibrosis

INTRODUCTION

This study aimed to compare the correlation between the computed tomography (CT) enhancement rate of the venous to portal venous phase (VP-ER) and the extracellular volume (ECV) fraction with shear-wave ultrasound elastography (USE) findings in patients with liver fibrosis.

METHODS

We included 450 patients with clinically suspected liver cirrhosis who underwent triphasic dynamic CT studies and USE. We compared the USE results with the unenhanced CT phase, with enhancement in the hepatic artery phase (HAP), portal venous phase (PVP), and venous phase (VP), and with the ECV fraction and the VP-ER. We also compared the area under the curve (AUC) of the receiver operating characteristic (ROC) curve of the ECV fraction and VP-ER with that of the values obtained with USE.

RESULTS

The VP-ER was the most highly correlated with the liver stiffness value determined with USE (Pearson's correlation coefficient: r = 0.37), followed by enhancement in the PVP (r = -0.25), CT number on unenhanced CT scans (r = -0.22), the ECV fraction (r = 0.19), enhancement in the VP (r = 0.059), and enhancement in the HAP (r = -0.023) (all p < 0.01). The VP-ER showed a significantly higher AUC than the ECV fraction (0.75 vs 0.62) when the liver stiffness was >15 kPa in USE studies (p = 0.04).

CONCLUSION

Compared to the ECV fraction, the VP-ER is more useful for predicting all degrees of liver fibrosis on routine triphasic dynamic CT images.

IMPLICATIONS FOR PRACTICE

Although improvement is needed, the VP-ER has a higher diagnostic ability for liver fibrosis than the ECV fraction in clinical practice.

Contrast media injection protocol for portovenous phase abdominal CT: does a fixed injection duration improve hepatic enhancement over a fixed injection rate?

PURPOSE

To assess whether a fixed contrast media (CM) injection duration improves the magnitude and inter-patient variability in hepatic enhancement over a fixed injection rate.

METHODS

Outpatients who underwent portovenous phase abdominal CT (fixed duration, February-November 2018; fixed rate, January-July 2020) with 1.22 mL/kg iohexol 350 were included. Subjects with liver, kidney or heart disease were excluded. The number of subjects and injection protocols were as follows: fixed duration arm, 56 women, 60 men, 35 s injection duration; fixed rate arm, 66 women, 62 men, 3 mL/s injection rate. Liver attenuation measurements were obtained from regions of interest on pre- and post-contrast images. Mean hepatic enhancement (MHE) and MHE normalized to iodine dose (MHE/I) were compared (unpaired t-tests and F-tests).

RESULTS

There was no statistically significant difference in age, weight, body mass index or CM dosing (p > 0.05). Enhancement indices were significantly lower in the fixed rate group as compared to the fixed duration group, as follows: MHE, 50.0 ± 12 vs. 54.8 ± 11 HU (p = 0.001); and MHE/I, 1.53 ± 0.43 vs. 1.66 ± 0.51 HU/g, (p = 0.04). However, there was no significant difference in the variances of MHE (p = 0.51) and MHE/I (p = 0.08).

CONCLUSION

A fixed CM injection duration yields a greater magnitude in hepatic enhancement indices than a fixed injection rate. Inter-patient variability in hepatic enhancement indices do not significantly differ between the two injection protocols.

Contrast media dose adjustment to allometric parameters of body mass in multiphasic CT of the liver: A comparison of different metrics

PURPOSE

To assess correlations of lean body weight (LBW) calculated with various formulas, total body weight (TBW), body height (BH), body mass index (BMI), body surface area (BSA) and fat-free mass (FFM) with vascular and parenchymal enhancement in multiphasic CT of the liver.

METHOD

Thirty consecutive patients underwent multiphasic CT of the liver using constant iodine dose and flow rate. Contrast enhancement of aorta, portal vein and liver was calculated by measuring mean vascular and parenchymal attenuation in pre-contrast and post-contrast phases. Correlations of TBW, BH, BMI, BSA, FFM, and LBW (calculated with formulas of Boer, Hume, James and Green&Duffull) with enhancement were tested using Spearman's correlation coefficient. The method of Fieller et al. was used to calculate 95 % confidence intervals. A p-value ≤ 0.05 was considered statistically significant.

RESULTS

Aortal enhancement correlated strongly with TBW, BSA, LBW_Boer and LBW_Hume and moderately with BH, BMI, FFM, LBW_James and LBW_{Green&Duffull}. Liver enhancement in the late arterial phase correlated moderately with TBW, FFM, LBW_Boer, LBW_Hume and LBW_{Green&Duffull} and weakly with BSA. Liver enhancement in the portal venous phase correlated strongly with TBW, BSA, FFM, LBW_Boer, LBW_Hume and LBW_{Green&Duffull}, whereby overlap of the 95 % CI graphs demonstrated that the differences in the correlation coefficients were not statistically significant. Liver enhancement in the delayed phase correlated moderately with BH but did not correlate significantly with any other parameter.

CONCLUSION

Regardless of the form used for calculation, LBW did not correlate statistically significantly stronger than TBW with vascular or parenchymal enhancement of the liver.

Prospective multicenter study on personalized and optimized MDCT contrast protocols: results on liver enhancement

OBJECTIVE

To determine a personalized and optimized contrast injection protocol for a uniform and optimal diagnostic level of liver parenchymal enhancement, in a large patient population enrolled in a multicenter study.

METHODS

Six hundred ninety-two patients who underwent a standardized multi-phase liver CT examination were prospectively assigned to one contrast media (CM) protocol group: G1 (100 mL fixed volume, 37 gI); G2 (600 mgI/kg of total body weight (TBW)); G3 (750 mgI/kg of fat-free mass (FFM)), and G4 (600 mgI/kg of FFM). Change in liver parenchyma CT number between unenhanced and contrast-enhanced images was measured by two radiologists, on 3-mm pre-contrast and portal phase axial reconstructions. The enhancement histograms were compared across CM protocols, specifically according to a target diagnostic value of 50 HU. The total amount of iodine dose was also compared among protocols by median and interquartile range (IQR). The Kruskal-Wallis and Mann-Whitney U tests were used to assess significant differences (p < 0.005), as appropriate.

RESULTS

A significant difference (p < 0.001) was found across the groups with liver enhancement decreasing from median over-enhanced values of 77.0 (G1), 71.3 (G2), and 65.1 (G3) to a target enhancement of 53.2 HU for G4. Enhancement IQR was progressively reduced from 26.5 HU (G1), 26.0 HU (G2), and 17.8 HU (G3) to 14.5 HU (G4). G4 showed a median iodine dose of 26.0 gI, significantly lower (p < 0.001) than G3 (33.9 gI), G2 (38.8 gI), and G1 (37 gI).

CONCLUSIONS

The 600 mgI/kg FFM-based protocol enabled a diagnostically optimized liver enhancement and improved patient-to-patient enhancement uniformity, while significantly reducing iodine load.

KEY POINTS

• Consistent and clinically adequate liver enhancement is observed with personalized and optimized contrast injection protocol. • Fat-free mass is an appropriate body size parameter for correlation with liver parenchymal enhancement. • Diagnostic oncology follow-up liver CT examinations may be obtained using 600 mgI/kg of FFM.

Optimization of contrast medium volume for abdominal CT in oncologic patients: prospective comparison between fixed and lean body weight-adapted dosing protocols

Background

Patient body size represents the main determinant of parenchymal enhancement and by adjusting the contrast media (CM) dose to patient weight may be a more appropriate approach to avoid a patient over dosage of CM. To compare the performance of fixed-dose and lean body weight (LBW)-adapted contrast media dosing protocols, in terms of image quality and parenchymal enhancement.

Results

One-hundred cancer patients undergoing multiphasic abdominal CT were prospectively enrolled in this multicentric study and randomly divided in two groups: patients in fixed-dose group (n = 50) received 120 mL of CM while in LBW group (n = 50) the amount of CM was computed according to the patient’s LBW. LBW protocol group received a significantly lower amount of CM (103.47 ± 17.65 mL vs. 120.00 ± 0.00 mL, p < 0.001). Arterial kidney signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) and pancreatic CNR were significantly higher in LBW group (all p ≤ 0.004). LBW group provided significantly higher arterial liver, kidney, and pancreatic contrast enhancement index (CEI) and portal venous phase kidney CEI (all p ≤ 0.002). Significantly lower portal vein SNR and CNR were observed in LBW-Group (all p ≤ 0.020).

Conclusions

LBW-adapted CM administration for abdominal CT reduces the volume of injected CM and improves both image quality and parenchymal enhancement.

Optimization of computed tomography contrast studies with a new, simple dosing regimen incorporating body size: examination of contrast effects in the thoracoabdominal aorta

The dosage of contrast agents for computed tomography contrast studies is calculated based on the parameter of actual body weight (ABW) to ensure reproducibility. The use of lean body weight (LBW) and adjustment for physique (lean or obese) improves accuracy. However, this method is complex, because LBW is not a general body parameter and requires a special device to measure. To solve this problem, contrast body weight (CBW), has been proposed as a new and simple parameter that considers physique. CBW is calculated by determining the blood volume ratio based on body height, ABW, and sex and can potentially correct for body size. It can be calculated by entering a formula in a Microsoft Excel sheet. Since CBW can be easily obtained using this general tool, we decided to compare the two body parameters of ABW and CBW. We compared ABW and CBW and demonstrated a higher correlation between CBW-based dosing and the amount of iodine used per body weight than with ABW-based dosing. CBW-based dosing allows correction for body size. This indicates that contrast enhancement over a spectrum of lean or obese examinees can be linearly evaluated. To date, this method has shown good results.

Aorta, liver, and portal vein CT contrast enhancement during the portal venous phase are positively associated with abdominal fat percentage in dogs

Contrast-enhanced computed tomography (CT) is increasingly being used as a standard diagnostic test for dogs with suspected abdominal pathology. The iodinated contrast dose is commonly calculated based on linear increases in total body weight. However, body fat is not metabolically active and contributes little to dispersing or diluting the contrast medium in the blood. The aim of this retrospective single-center analytic study was to investigate the possible correlation between abdominal organ and vessel enhancement, and abdominal fat percentage in dogs. We hypothesized that, when dosing intravenous iodinated contrast according to total body weight, there would be a positive association between the degree of contrast enhancement of selected organs and vessels with increasing abdominal fat percentage. Vascular and parenchymal attenuation data were collected from 62 multiphasic abdominal CECT scans performed on dogs over a 5-year period at U-Vet Werribee Animal Hospital between February 2014 and February 2019. Findings based on a linear regression model showed a positive association of aorta (P = .005), liver (P = .045), and portal vein (P = .001) enhancement to abdominal fat percentage during the portal venous phase. Authors recommend that other body size parameters, such as lean body weight, should be considered when calculating iodine dose for abdominal contrast-enhanced CT in dogs.

[A New Method for Calculating Iodine Dose in Abdominal Dynamic Contrast-enhanced Computed Tomography: Calculation Based on Patients' Body Size Parameters and Estimated Volume of Distribution of Non-ionic Contrast Medium]

PURPOSE

This study aimed at analyzing the relationship between the estimated volume of distribution on computed tomography (eVd_CT) of non-ionic contrast medium and four different patients' body size parameters (BSPs) (total body weight, body mass index, body surface area, and lean body weight) in abdominal dynamic contrast-enhanced computed tomography (ADCE-CT) . Moreover, this study intended to derive a method for calculating the iodine dose to target contrast enhancement.

METHODS

We measured enhanced CT values of the equilibrium phase of the abdominal aorta in 527 patients who underwent ADCE-CT. The eVd_CT of the ADCE-CT equilibrium phase was calculated from enhanced CT values based on the pharmacokinetic model. The optimal iodine dose (OID) was calculated from the regression analysis of eVd_CT and BSP.

RESULTS

The eVd_CT was 7741.1±1799.5 ml. The eVd_CT showed a strong positive correlation with BSP and could be calculated using a linear regression equation. The correlation coefficients for total body weight, body surface area, and lean body weight were 0.83, 0.84, and 0.81, respectively. The OID per unit BSP required for target iodine concentration of the abdominal aorta on ADCE-CT (TIC) could be calculated as "OID [mgI/BSP]=[(a･BSP+b)×TIC]/BSP".

CONCLUSION

The OID calculation method based on the patients' body size parameters and estimated volume of distribution can normalize contrast enhancement in abdominal dynamic contrast-enhanced CT.

Pancreatic perfusion imaging method that reduces radiation dose and maintains image quality by combining volumetric perfusion CT with multiphasic contrast enhanced-CT

OBJECTIVES

The aim of this study is to propose and evaluate a new method of volumetric perfusion computed tomography (PCT) incorporated into pancreatic multiphasic contrast enhanced (CE)-CT in the clinical setting.

METHODS

In this ethically approved study, PCT was incorporated into our existing scanning protocol in 17 patients and effective doses related to PCT were evaluated. CT values and signal-to-noise ratio (SNR) of anatomical structure were compared in diagnostic images that were acquired using 320-detector volumetric scan mode and 64-detector helical scan mode. In addition, focal lesion depiction was qualitatively assessed in the two groups. Perfusion parameters in normal pancreas were measured by two radiologists and the interobserver-reliability was assessed.

RESULTS

The effective dose of PCT was 5.1 ± 0.3 mSv. The actual effective dose (AED) including the dose used in volumetric scans for diagnostic imaging was 22.8 ± 5.3 mSv and the putative effective dose (PED) was 21.9 ± 9.1 mSv on average. There was no significant difference between AED and PED (p = 0.404). Compared with conventional helical scans, volumetric scans did not decrease CT values or SNR, but rather significantly increased those of the aorta in the arterial phase. Both groups had acceptable qualitatively assessed image quality with no significant difference in the depiction of each structure. There was almost perfect interobserver agreement in the measurement of perfusion parameters (mean ICCs > 0.9).

CONCLUSIONS

Our scanning protocol for pancreatic perfusion CT provides high-quality images while requiring lower radiation doses than conventional methods.

A Solution for Homogeneous Liver Enhancement in Computed Tomography: Results From the COMpLEx Trial

OBJECTIVES

The aim of the study was to reach homogeneous enhancement of the liver, irrespective of total body weight (TBW) or tube voltage. An easy-to-use rule of thumb, the 10-to-10 rule, which pairs a 10 kV reduction in tube voltage with a 10% decrease in contrast media (CM) dose, was evaluated.

MATERIALS AND METHODS

A total of 256 patients scheduled for an abdominal CT in portal venous phase were randomly allocated to 1 of 4 groups. In group 1 (n = 64), a tube voltage of 120 kV and a TBW-adapted CM injection protocol was used: 0.521 g I/kg. In group 2 (n = 63), tube voltage was 90 kV and the TBW-adapted CM dosing factor remained 0.521 g I/kg. In group 3 (n = 63), tube voltage was reduced by 20 kV and CM dosing factor by 20% compared with group 1, in line with the 10-to-10 rule (100 kV; 0.417 g I/kg). In group 4 (n = 66), tube voltage was decreased by 30 kV paired with a 30% decrease in CM dosing factor compared with group 1, in line with the 10-to-10 rule (90 kV; 0.365 g I/kg). Objective image quality was evaluated by measuring attenuation in Hounsfield units (HU), signal-to-noise ratio, and contrast-to-noise ratio in the liver. Overall subjective image quality was assessed by 2 experienced readers by using a 5-point Likert scale. Two-sided P values below 0.05 were considered significant.

RESULTS

Mean attenuation values in groups 1, 3, and 4 were comparable (118.2 ± 10.0, 117.6 ± 13.9, 117.3 ± 21.6 HU, respectively), whereas attenuation in group 2 (141.0 ± 18.2 HU) was significantly higher than all other groups (P < 0.01). No significant difference in attenuation was found between weight categories 80 kg or less and greater than 80 kg within the 4 groups (P ≥ 0.371). No significant differences in subjective image quality were found (P = 0.180).

CONCLUSIONS

The proposed 10-to-10 rule is an easily reproducible method resulting in similar enhancement in portal venous CT of the liver throughout the patient population, irrespective of TBW or tube voltage.

More holes, more contrast? Comparing an 18-gauge non-fenestrated catheter with a 22-gauge fenestrated catheter for cardiac CT

Objective

To compare the performance of an 18-gauge nonfenestrated catheter (18-NFC) with a 22-gauge fenestrated catheter (22-FC) for cardiac CT angiography (CCTA) in patients with suspected coronary heart disease.

Subjects and methods

74 consecutive patients imaged on a 2^nd generation dual-source CT with arterial phase CCTA were included in this retrospective investigation to either an 18-NFC or 22-FC. In comparison to the 18-NFC, the 22-FC has three additional perforations for contrast agent dispersal proximal to the tip. We examined the two groups for differences in their average attenuation in the right and left ventricles (RV, LV) and in the atrium (RA, LA) as well as in the proximal right coronary artery (RCA) and the left main coronary artery (LM). The averages were calculated for both the 18-NFC and 22-FC.

Results

Catheters were successfully placed on the first attempt 97% (36/37) for 18-NFC and 95% (35/37) for the 22-FC. The following enhancement levels were measured: 22-FC (in Hounsfield-Units (HU)): RV = 203±29, LV = 523±36, RA = 198±29, LA = 519±38, RCA = 547±26, LM = 562±25; 18-NFC: RV = 146±26, LV = 464±32, RA = 141±24, LA = 438±35, RCA = 501±23, LM = 523±23; RV (p = 0,03), LV (p = 0.12), RA (p = 0.02), LA (p = 0.04), RCA (p = 0.3), LM (p = 0.33).

Conclusion

No significant differences in attenuation levels as well as in image quality of the coronary arteries were found between NFC and FC. Nevertheless, the 22-gauge FC examinations showed significantly higher attenuation in the left and right atrium as well as the right ventricle. Patients with poor venous access may benefit from a smaller gauge catheter that can deliver sufficiently high flow rates for CCTA.

Dosing Iodinated Contrast Media According to Lean Versus Total Body Weight at Abdominal CT: A Stratified Randomized Controlled Trial

RATIONALE AND OBJECTIVES

To compare the magnitude and interpatient variability in normalized mean hepatic enhancement (MHE) indices when dosing contrast media (CM) according to total body weight (TBW) and lean body weight (LBW).

MATERIALS AND METHODS

This ethics-approved stratified randomized controlled study allocated 280 outpatients for abdominal Computed Tomography (CT) between February-November 2018 to TBW- or LBW-dosing using computer-generated tables. CTs were acquired in portal venous phase after fixed 35-second injection of Iohexol 350. Patients with missing precontrast image, incorrect dose, or chronic kidney, liver or heart disease were excluded. The number of included patients and CM doses were: TBW arm, 51 women and 60 men, 1.22 mL/kg; LBW arm, 59 women, 1.66 mL/kg LBW, and 59 men, 1.52 mL/kg LBW. Liver attenuations were obtained from regions of interest. Values and standard deviations in MHE indices normalized to iodine dose (MHE/I) and iodine dose per kg TBW (aMHE = MHE/[I/TBW]) were compared (unpaired t tests and F-tests).

RESULTS

Cohorts were similar in age, sex, TBW, and LBW. TBW groups received more CM than LBW groups: men, 106.5 ± 20 versus 98.4 ± 11 mL, p = 0.007; women, 93.7 ± 20 versus 77.5 ± 11 mL, p < 0.0001. TBW and LBW groups showed no significant difference in MHE/I (women, 1.75 ± 0.5 versus 1.86 ± 0.6 HU/g, p = 0.31; men, 1.53 ± 0.4 versus 1.52 ± 0.4 HU/g, p = 0.90) or aMHE (women, 0.03 ± 0.01 versus 0.03 ± 0.01 HU/g/kg, p = 0.25; men, 0.02 ± 0.01 versus 0.02 ± 0.01 HU/g/kg, p = 0.52). Variances in MHE/I and aMHE were not significantly different for all groups (p > 0.05).

CONCLUSION

TBW- and LBW-based CM dosing yield a similar magnitude and interpatient variability in normalized MHE indices at routine abdominal CT.

Individual Optimization of Contrast Media Injection Protocol at Hepatic Dynamic Computed Tomography Using Patient-Specific Contrast Enhancement Optimizer

OBJECTIVE

We developed a patient-specific contrast enhancement optimizer (p-COP) that can exploratorily calculate the contrast injection protocol required to obtain optimal enhancement at target organs using a computer simulator. Appropriate contrast media dose calculated by the p-COP may minimize interpatient enhancement variability. Our study sought to investigate the clinical utility of p-COP in hepatic dynamic computed tomography (CT).

METHODS

One hundred thirty patients (74 men, 56 women; median age, 65 years) undergoing hepatic dynamic CT were randomly assigned to 1 of 2 contrast media injection protocols using a random number table. Group A (n = 65) was injected with a p-COP-determined iodine dose (developed by Higaki and Awai, Hiroshima University, Japan). In group B (n = 65), a standard protocol was used. The variability of measured CT number (SD) between the 2 groups of aortic and hepatic enhancement was compared using the F test. In the equivalence test, the equivalence margins for aortic and hepatic enhancement were set at 50 and 10 Hounsfield units (HU), respectively. The rate of patients with an acceptable aortic enhancement (250-350 HU) for the diagnosis of hypervascular liver tumors was compared using the χ test.

RESULTS

The mean ± SD values of aortic and hepatic enhancement were 311.0 ± 39.9 versus 318.7 ± 56.5 and 59.0 ± 11.5 versus 58.6 ± 11.8 HU in groups A and B, respectively. Although the SD for aortic enhancement was significantly lower in group A (P = 0.006), the SD for hepatic enhancement was not significantly different (P = 0.871). The 95% confidence interval for the difference in aortic and hepatic enhancement between the 2 groups was within the range of the equivalence margins. The number of patients with acceptable aortic enhancement was significantly greater in group A than in group B (P < 0.01).

CONCLUSIONS

The p-COP software reduced interpatient variability in aortic enhancement and obtained acceptable aortic enhancement at a significantly higher rate compared with the standard injection protocol for hepatic dynamic CT.

Acute kidney injury from contrast-enhanced CT procedures in patients with cancer: white paper to highlight its clinical relevance and discuss applicable preventive strategies

Patients with cancer are subjected to several imaging examinations which frequently require the administration of contrast medium (CM). However, it has been estimated that acute kidney injury (AKI) due to the injection of iodinated CM accounts for 11% of all cases of AKI, and it is reported in up to 2% of all CT examinations. Remarkably, the risks of developing AKI are increased in the elderly, in patients with chronic kidney disease or diabetes, and with dehydration or administration of nephrotoxic chemotherapeutics. Given the common occurrence of postcontrast acute kidney injury (PC-AKI) in clinical practice, primary care physicians and all specialists involved in managing patients with cancer should be aware of the strategies to reduce the risk of this event. In 2018, a panel of four experts from the specialties of radiology, oncology and nephrology were speakers at the annual meeting of the Italian Society of Medical Radiology (Società Italiana di Radiologia Medica e Interventistica), with the aim of commenting on existing evidence and providing their experience on the incidence and management of PC-AKI in patients with cancer. The discussion represented the basis for this white paper, which is intended to be a practical guide organised by statements describing methods to reduce renal injury risks related to CM-enhanced CT examinations in patients with cancer.

Contrast medium injection protocols for coronary CT angiography: should contrast medium volumes be tailored to body weight or body surface area?

AIM

To compare the uniformity and image quality between contrast media injection protocols adjusted for patient body weight (BW) versus body surface area (BSA) during coronary computed tomography (CT) angiography (CCTA).

MATERIALS AND METHODS

Consecutive patients (n=489) with suspected coronary artery disease were randomised prospectively to one of two CCTA protocols. In the BW protocol (n=245), patients received individualised iodine delivery rates (≤50 kg: 1 g/s; 51-60 kg: 1.2 g/s; 61-70 kg: 1.4 g/s; 71-80 kg: 1.6 g/s; 81-90 kg: 1.8 g/s; 91-100 kg: 2 g/s; >100 kg: 2.2 g/s). In the BSA protocol (n=244), patients received 9,600 mg iodine/m² of contrast medium over 12 seconds. Attenuation and image noise were measured. Signal-to-noise ratio and contrast-to-noise ratio were calculated. Image quality was scored. Attenuation was assessed for correlation with BW and BSA using linear regression.

RESULTS

There were no statistically significant differences in mean arterial attenuation (396.8±47.6 versus 395.8±42.2 HU, p=0.804; 95% confidence interval: -7 to 9), image noise (25.2±5.8 versus 25.5±5.4 HU; p=0.549), signal-to-noise ratio (16.7±4.4 versus 16.6±3.6; p=0.902), contrast-to-noise ratio (25.1±5.8 versus 25.8±7.4; p=0.258) or image quality scores (4.1±0.9 versus 4±0.9; p=0.770) between the BW and BSA protocols. There was no correlation between BW and aortic attenuation or between BSA and aortic attenuation (p=0.324 and 0.932, respectively).

CONCLUSION

The average contrast media attenuation and image quality was comparable between BW-adjusted protocol and BSA-adjusted protocol.

Individually Body Weight-Adapted Contrast Media Application in Computed Tomography Imaging of the Liver at 90 kVp

OBJECTIVES

The aim of the present study was to evaluate the attenuation and image quality (IQ) of a body weight-adapted contrast media (CM) protocol compared with a fixed injection protocol in computed tomography (CT) of the liver at 90 kV.

MATERIALS AND METHODS

One hundred ninety-nine consecutive patients referred for abdominal CT imaging in portal venous phase were included. Group 1 (n = 100) received a fixed CM dose with a total iodine load (TIL) of 33 g I at a flow rate of 3.5 mL/s, resulting in an iodine delivery rate (IDR) of 1.05 g I/s. Group 2 (n = 99) received a body weight-adapted CM protocol with a dosing factor of 0.4 g I/kg with a subsequent TIL adapted to the patients' weight. Injection time of 30 seconds was kept identical for all patients. Therefore, flow rate and IDR changed with different body weight. Patients were divided into 3 weight categories; 70 kg or less, 71 to 85 kg, and 86 kg or greater. Attenuation (HU) in 3 segments of the liver, signal-to-noise ratio, and contrast-to-noise ratio were used to evaluate objective IQ. Subjective IQ was assessed by a 5-point Likert scale. Differences between groups were statistically analyzed (P < 0.05 was considered statistically significant).

RESULTS

No significant differences in baseline characteristics were found between groups. The CM volume and TIL differed significantly between groups (P < 0.01), with mean values in group 1 of 110 mL and 33 g I, and in group 2 of 104.1 ± 21.2 mL and 31.2 ± 6.3 g I, respectively. Flow rate and IDR were not significantly different between groups (P > 0.05). Body weight-adapted protocoling led to more homogeneous enhancement of the liver parenchyma compared with a fixed protocol with a mean enhancement per weight category in group 2 of 126.5 ± 15.8, 128.2 ± 15.3, and 122.7 ± 21.2 HU compared with that in group 1 of 139.9 ± 21.4, 124.6 ± 24.8, and 116.2 ± 17.8 HU, respectively.

CONCLUSIONS

Body weight-adapted CM injection protocols result in more homogeneous enhancement of the liver parenchyma at 90 kV in comparison to a fixed CM volume with comparable objective and subjective IQ, whereas overall CM volume can be safely reduced in more than half of patients.

Determination of contrast medium dose for hepatic CT enhancement with improved body size dependency using a non-linear analysis based on pharmacokinetic principles

AIM

To propose a pharmacokinetic non-linear analysis method to determine contrast medium (CM) dose for computed tomography (CT) hepatic enhancement to improve body size dependency and validate the proposed CM dose determination method through a clinical study.

MATERIALS AND METHODS

Enhancement data of 105 patients who underwent hepatic dynamic CT with a fixed CM dose were analysed. From the analysis results, CM doses as a function of each of four body size indices (body weight [BW], lean body weight [LBW], blood volume [BV], and body surface area [BSA]) for achieving improved body size dependency were determined (proposed method), and the body size dependencies were simulated using the enhancement data from 105 patients. The proposed method was validated with a two-arm clinical study on BW. Body size dependency was evaluated using p-value of correlation coefficient between Body size indices and enhancements (p<0.05: significant dependency) and mean absolute error (MAE).

RESULTS

The simulation showed that significant body size dependencies not considered by the conventional method can be improved by the proposed method. MAEs of BW, LBW, and BV were also significantly reduced (p<0.05). The clinical study with BW demonstrated a similar improvement to that in the simulation result. MAE was also significantly reduced (p<0.001).

CONCLUSION

The proposed method demonstrated more improved BW, LBW, and BV dependence compared to the conventional method. Through the two-arm clinical study, the proposed method using BW only, without height information, is a suitable index for improving body size dependency.

Contrast enhancement on 100- and 120 kVp hepatic CT scans at thin adults in a retrospective cohort study: Bayesian inference of the optimal enhancement probability

PURPOSE

To assess the probability of achieving optimal contrast enhancement in 100 kVp and 120 kVp-protocol on hepatic computed tomography (CT) scans.

MATERIALS AND METHODS

We enrolled 200 patients in a retrospective cohort study. Hundred patients were scanned with 120 kVp setting, and other 100 patients were scanned with 100 kVp setting. We measured the CT number in the abdominal aorta and hepatic parenchyma on unenhanced scans and hepatic arterial phase (HAP)-, and portal venous phase (PVP). The aortic enhancement at HAP and the hepatic parenchymal enhancement at PVP were compared between the two scanning protocols. Bayesian inference was used to assess the probability of achieving optimal contrast enhancement in each protocol.

RESULTS

The Bayesian analysis indicated that when 100 kVp-rotocol was used, the probability of achieving optimal aortic enhancement (>280 HU) was 98.8% ± 0.6%, whereas it was 88.7% ± 2.5% when 120 kVp-protocol was used. Also, the probability of achieving optimal hepatic parenchymal enhancement (>50 HU) was 95.3% ± 1.5%, whereas it was 64.7% ± 3.8% when 120 kVp-protocol was used.

CONCLUSION

Bayesian inference suggested that the post-test probability of optimal contrast enhancement at hepatic dynamic CT was lower under the 120 kVp than the 100 kVp-protocol.

Contrast Material Injection Protocol With the Dose Determined According to Lean Body Weight at Hepatic Dynamic Computed Tomography: Comparison Among Patients With Different Body Mass Indices

OBJECTIVE

The objective of this study was to compare enhancement of the aorta and liver on hepatic dynamic computed tomography scans acquired with contrast material doses based on the lean body weight (LBW) or the total body weight (TBW).

METHODS

We randomly divided 529 patients (279 men, 250 women; median age, 66 years) scheduled for hepatic dynamic computed tomography into 2 groups. The LBW patients (n = 278) were injected with 679 mg iodine/kg (men) or 762 mg iodine/kg (women). The TBW group (n = 251) was injected with 600 mg iodine/kg TBW. Each group was subdivided into the 3 classes based on the body mass index (BMI; low, normal, high). Aortic enhancement during the hepatic arterial phase and hepatic enhancement during the portal venous phase was compared. The aortic and hepatic equivalence margins were 100 and 20 Hounsfield units, respectively.

RESULTS

Comparison of the median iodine dose in patients with a normal or high BMI showed that it was significantly lower under the LBW protocol than the TBW protocol (558.2 and 507.0 mg iodine/kg, P < 0.001, respectively). However, in patients with a low BMI, the LBW protocol delivered a significantly higher dose than the TBW protocol (620.7 vs 600.0 mg iodine/kg, P < 0.001). The 95% confidence interval for the difference in aortic and hepatic enhancement between the 2 protocols was within the range of the predetermined equivalence margins in all BMI subgroups.

CONCLUSIONS

Contrast enhancement was equivalent under both protocols. The LBW protocol can avoid iodine overdosing, especially in patients with a high BMI.

Dual energy computed tomography analysis in cancer patients: What factors affect iodine concentration in contrast enhanced studies?

PURPOSE

The aim of the study is to explore the patient's and scan's parameters that affect the iodine concentration in the abdomen using dual energy computed tomography (DECT) in an oncologic population.

METHOD

This is a retrospective study with consecutive patients with different cancers who underwent a single-source DECT (ssDECT) examinations at our institution between years 2015 and 2017. On axial IODINE images, the radiologist manually drew a circular ROI along the inner contour of the aorta. Mean iodine concentration and ROI areas were recorded. Body mass index for every patient was recorded. Descriptive statistics were summarized for iodine concentration and patient/scan characteristics. Linear regression was used to examine associations between iodine concentration in aorta and studied characteristics. Statistical significance was set at a p value < 0.05.

RESULTS

The univariate analysis, showed a statistically significant association between iodine concentration within the aorta and the area of ROI (Estimated Coefficient β: -0.013), the rate of injection (Estimated Coefficient β: 2.09), the acquisition time (Estimated Coefficient β: -0.195). In multivariable analysis iodine concentration in the aorta increased with higher rate of injection (4 ml/sec), smaller ROI area and lower BMI.

CONCLUSION

Our results showed how iodine concentration is highly dependent on some intrinsic and extrinsic parameters of the examination. These parameters should be taken into account since lower concentration of iodine decrease contrast-to-noise ratio, and in longitudinal follow up studies, they would affect iodine quantitive assessments in cancer patients with frequent chemotherapy-induced variations in BMI and cardiac function.

Effect of Patient Characteristics on Vessel Enhancement in Pediatric Chest Computed Tomography Angiography

INTRODUCTION

To evaluate the effect of sex, age, height, cardiac output (CO), total body weight (TBW), body surface area (BSA), and lean body weight (LBW) on vessel enhancement of the ascending aorta in pediatric chest computed tomography angiography (c-CTA).

MATERIALS AND METHODS

This retrospective study received institutional review board approval; parental prior informed consent for inclusion was obtained for all patients. All 50 patients were examined using our routine protocol; iodine (600 mg/kg) was the contrast medium (CM). Unenhanced and contrast-enhanced scans were obtained. We calculated the CM volume per vessel enhancement and performed univariate and multivariate linear regression analysis of the relationship between CM volume per vessel enhancement and each of the body parameters.

RESULTS

All patient characteristics were significantly related to CM volume per vessel enhancement (P < .05). Multivariate linear regression analysis revealed a significant correlation between CM volume per vessel enhancement and TBW, BSA, and LBW, but not the patient sex, age, CO, and height. The LBW model for CM volume per vessel enhancement yielded the highest determination coefficient (R² = .913) and the lowest Akaike Information Criterion (400.324).

CONCLUSIONS

Our findings support the delivery of an iodine dose adjusted to the LBW at c-CTA.

Abdominal CT: a radiologist-driven adjustment of the dose of iodinated contrast agent approaches a calculation per lean body weight

Background

The contrast agent (CA) dose for abdominal computed tomography (CT) is typically based on patient total body weight (TBW), ignoring adipose tissue distribution. We report on our experience of dosing according to the lean body weight (LBW).

Methods

After Ethics Committee approval, we retrospectively screened 219 consecutive patients, 18 being excluded for not matching the inclusion criteria. Thus, 201 were analysed (106 males), all undergoing a contrast-enhanced abdominal CT with iopamidol (370 mgI/mL) or iomeprol (400 mgI/mL). LBW was estimated using validated formulas. Liver contrast-enhancement (CE_L) was measured. Data were reported as mean ± standard deviation. Pearson correlation coefficient, ANOVA, and the Levene test were used.

Results

Mean age was 66 ± 13 years, TBW 72 ± 15 kg, LBW 53 ± 11 kg, and LBW/TBW ratio 74 ± 8%; body mass index was 26 ± 5 kg/m², with 9 underweight patients (4%), 82 normal weight (41%), 76 overweight (38%), and 34 obese (17%). The administered CA dose was 0.46 ± 0.06 gI/kg of TBW, corresponding to 0.63 ± 0.09 gI/kg of LBW. A negative correlation was found between TBW and CA dose (r = -0.683, p < 0.001). CE_L (Hounsfield units) was 51 ± 18 in underweight patients, 44 ± 8 in normal weight, 42 ± 9 in overweight, and 40 ± 6 in obese, with a significant difference for both mean (p = 0.004) and variance (p < 0.001). A low but significant positive correlation was found between CE_L and CA dose in gI per TBW (r = 0.371, p < 0.001) or per LBW (r = 0.333, p < 0.001).

Conclusions

The injected CA dose was highly variable, with obese patients receiving a lower dose than underweight patients, as a radiologist-driven ‘compensation effect’. Diagnostic abdomen CT examinations may be obtained using 0.63 gI/kg of LBW.

Development and Validation of Generalized Linear Regression Models to Predict Vessel Enhancement on Coronary CT Angiography

Objective

We evaluated the effect of various patient characteristics and time-density curve (TDC)-factors on the test bolus-affected vessel enhancement on coronary computed tomography angiography (CCTA). We also assessed the value of generalized linear regression models (GLMs) for predicting enhancement on CCTA.

Materials and Methods

We performed univariate and multivariate regression analysis to evaluate the effect of patient characteristics and to compare contrast enhancement per gram of iodine on test bolus (ΔHUTEST) and CCTA (ΔHUCCTA). We developed GLMs to predict ΔHUCCTA. GLMs including independent variables were validated with 6-fold cross-validation using the correlation coefficient and Bland–Altman analysis.

Results

In multivariate analysis, only total body weight (TBW) and ΔHUTEST maintained their independent predictive value (p < 0.001). In validation analysis, the highest correlation coefficient between ΔHUCCTA and the prediction values was seen in the GLM (r = 0.75), followed by TDC (r = 0.69) and TBW (r = 0.62). The lowest Bland–Altman limit of agreement was observed with GLM-3 (mean difference, −0.0 ± 5.1 Hounsfield units/grams of iodine [HU/gI]; 95% confidence interval [CI], −10.1, 10.1), followed by ΔHUCCTA (−0.0 ± 5.9 HU/gI; 95% CI, −11.9, 11.9) and TBW (1.1 ± 6.2 HU/gI; 95% CI, −11.2, 13.4).

Conclusion

We demonstrated that the patient's TBW and ΔHUTEST significantly affected contrast enhancement on CCTA images and that the combined use of clinical information and test bolus results is useful for predicting aortic enhancement.

Dual-layer dual-energy computed tomography for the assessment of hypovascular hepatic metastases: impact of closing k-edge on image quality and lesion detectability

OBJECTIVES

To evaluate the image quality of virtual-monoenergetic-imaging (VMI) from dual-layer dual-energy CT (DLCT) for the assessment of hypovascular liver metastases and its effect on lesion detectability.

METHODS

Eighty-one patients with hypovascular-liver-metastases undergoing portal-venous-phase abdominal DLCT were included. Polyenergetic-images (PEI) and VMI at 40-200 keV (VMI_40-200, 10-keV interval) were reconstructed. Image noise, tumor-to-liver contrast, and contrast-to-noise ratio (CNR) of hepatic parenchyma and metastatic nodules (n = 288) were measured to determine the optimal monoenergetic levels. Two radiologists independently and subjectively assessed the image quality (image contrast, image noise, and diagnostic confidence) of PEI and optimal VMI on 5-point scales to determine the best energy. For 38 patients having up to 10 metastases each with diameters < 25 mm (153 lesions), we compared blindly assessed lesion detectability and conspicuity between PEI and VMI at the best energy.

RESULTS

Image noise of VMI_40-200 was consistently lower than that of PEI (p < 0.01). Tumor-to-liver contrast and CNR increased as the energy decreased with CNR at VMI_40-70 being higher than that observed on PEI (p < 0.01). The highest subjective score for diagnostic confidence was assigned at VMI₄₀ followed by VMI_50-70, all of which were significantly better than that of PEI (p < 0.01, kappa = 0.75). Lesion detectability at VMI₄₀ was significantly superior to PEI, especially for lesions with diameters of < 10 mm (p < 0.01, kappa ≥ 0.6).

CONCLUSIONS

VMI_40-70 provided a better subjective and objective image quality for the evaluation of hypovascular liver metastases, and the lesion detectability was improved with use of VMI₄₀ compared with conventional PEI.

KEY POINTS

• DLCT-VMI at 40-70 keV provides a superior subjective and objective image quality compared with conventional PEI for the assessment of hypovascular hepatic metastases during portal venous phase. • Tumor-to-liver contrast and CNR of hypovascular hepatic metastases was maximized at 40 keV without a relevant increase in the image noise. • VMI at 40 keV yields a superior lesion detectability, especially for small (< 1 cm) metastatic nodules compared with conventional PEI.

Lean Body Weight-Tailored Iodinated Contrast Injection in Obese Patient: Boer versus James Formula

Purpose

To prospectively compare the performance of James and Boer formula in contrast media (CM) administration, in terms of image quality and parenchymal enhancement in obese patients undergoing CT of the abdomen.

Materials and Methods

Fifty-five patients with a body mass index (BMI) greater than 35 kg/m² were prospectively included in the study. All patients underwent 64-row CT examination and were randomly divided in two groups: 26 patients in Group A and 29 patients in Group B. The amount of injected CM was computed according to the patient's lean body weight (LBW), estimated using either Boer formula (Group A) or James formula (Group B). Patient's characteristics, CM volume, contrast-to-noise ratio (CNR) of liver, aorta and portal vein, and liver contrast enhancement index (CEI) were compared between the two groups. For subjective image analysis readers were asked to rate the enhancement of liver, kidneys, and pancreas based on a 5-point Likert scale.

Results

Liver CNR, aortic CNR, and portal vein CNR showed no significant difference between Group A and Group B (all P ≥ 0.177). Group A provided significantly higher CEI compared to Group B (P = 0.007). Group A and Group B returned comparable overall subjective enhancement values (3.54 and vs 3.20, all P ≥ 0.199).

Conclusions

Boer formula should be the method of choice for LBW estimation in obese patients, leading to an accurate CM amount calculation and an optimal liver contrast enhancement in CT.

Contrast Administration in CT: A Patient-Centric Approach

Patient-centric care has garnered the attention of the radiology community. The authors describe a patient-centric approach to iodinated contrast administration designed to optimize the diagnostic yield of contrast-enhanced CT while minimizing patient iodine load and exposure to ionizing radiation, thereby enhancing patient safety while providing reasonable diagnostic efficacy. Patient-centric CT hardware settings and contrast media administration are important considerations for clinical CT quality and safety.

Relationships between patient characteristics and contrast agent dose for successful computed tomography venography with a body-weight-tailored contrast protocol

The aim of this study was to evaluate the effect of patient characteristics on the contrast agent dosage that is required to reach effective enhancement of the inferior vena cava (IVC) on computed tomography venographs (CTV).This retrospective study included 50 patients who underwent CTV at 80 kVp. The contrast injection protocol (iodine 600 mg/kg) was tailored to their body weight. We calculated the required contrast agent volume (CAVmean-IVC) to reach the mean enhancement of IVC. We performed univariate and multivariate linear regression analyses between the sex, age, body weight (BW), lean body weight (LBW), body surface area (BSA), height (HT), estimated glomerular filtration rate (eGFR), and CAVmean-IVC.The univariate linear regression analysis show that HT, BW, LBW, and BSA were significantly correlated with CAVmean-IVC (P < .01 for all). The CAVmean-IVC was significantly higher for males than females (P < .01). Multivariate regression analysis showed that BW, LBW, and BSA had a statistically significant effect on CAVmean-IVC. There was no significant correlation of age, HT, or eGFR with CAVmean-IVC.BW, LBW, and BSA each had an independent significant effect on CAVmean-IVC. The conventional BW-tailored contrast injection protocol might be insufficient for CTV.

Effect of Patient Characteristics on Vessel Enhancement at Lower Extremity CT Angiography

Objective

To evaluate the effect of patient characteristics on popliteal aortic contrast enhancement at lower extremity CT angiography (LE-CTA) scanning.

Materials and Methods

Prior informed consent to participate was obtained from all 158 patients. All were examined using a routine protocol; the scanning parameters were tube voltage 100 kVp, tube current 100 mA to 770 mA (noise index 12), 0.5-second rotation, 1.25-mm detector row width, 0.516 beam pitch, and 41.2-mm table movement, and the contrast material was 85.0 mL. Cardiac output (CO) was measured with a portable electrical velocimeter within 5 minutes of starting the CT scan. To evaluate the effects of age, sex, body size, CO, and scan delay on the CT number of popliteal artery, the researchers used multivariate regression analysis.

Results

A significant positive correlation was seen between the CT number of the popliteal artery and the patient age (r = 0.39, p < 0.01). A significant inverse correlation was observed between the CT number of the popliteal artery and the height (r = −0.48), total body weight (r = −0.52), body mass index (r = −0.33), body surface area (BSA) (r = −0.56), lean body weight (r = −0.56), and CO (r = −0.35) (p < 0.001 for all). There was no significant correlation between the enhancement and the scan delay (r = 0.06, p = 0.47). The BSA, CO, and age had significant effects on the CT number (standardized regression: BSA −0.42, CO −0.22, age 0.15; p < 0.05, respectively).

Conclusion

The BSA, CO, and age are significantly correlated with the CT number of the popliteal artery on LE-CTA.

[Effect of Tube Voltage on Contrast Enhancement and Contrast Medium Dose in Abdominal Contrast-enhanced Computed Tomography]

The purpose of this study was to investigate the effect of tube voltage on relationship between a patient's body weight and contrast enhancement in abdominal contrast-enhanced computed tomography (CT). Five phantoms with diameters ranging from 19.2 to 30.6 cm, including syringes filled with iodine solution diluted to different concentrations, were used to compare the effects at tube voltages of 80, 100, and 120 kVp. Furthermore, for clinical study, 300 patients who underwent abdominal contrast-enhanced CT examinations were enrolled and enhancements of aorta and hepatic parenchyma in arterial phase and equilibrium phase were compared at 80, 100, and 120 kVp using a contrast medium administration proportional to the body weight. The contrast enhancement was decreased with increase in phantom size because of the beam-hardening effect, and however, the decrease was less at low tube voltages of 80 and 100 kVp (lowest at 80 kVp), demonstrating the beam-hardening effect was reduced at low tube voltages. The enhancements of aorta and hepatic parenchyma indicated tended to increase in patients with a heavy body weight, and this trend was stronger at 80 and 100 kVp (80 kVp>100 kVp). Therefore, it was indicated that the problem of excessive contrast enhancement in patients with a high body weight was prominent at low tube voltages because the beam-hardening effect in patients with a heavy body weight was weaken by low tube voltages.

LI-RADS technical requirements for CT, MRI, and contrast-enhanced ultrasound

Accurate detection and characterization of liver observations to enable HCC diagnosis and staging using LI-RADS requires a technically adequate imaging exam. To help achieve this objective, LI-RADS has proposed technical requirements for CT, MR, and contrast-enhanced ultrasound of liver. This article reviews the technical requirements for liver imaging, including the description of minimum acceptable technical standards, such as the scanner hardware requirements, recommended dynamic imaging phases, and common technical challenges of liver imaging.